Mallinckrodt expands platform with Questcor purchase
Dublin, Ireland-based Mallinckrodt Pharmaceuticals plc has broadened its strategic product growth platform with the $5.6 billion acquisition of Questcor Pharmaceuticals Inc.
Questcor's major product is Acthar gel, a depot injectable corticosteroid approved by the Food and Drug Administration for 19 conditions, mostly autoimmune and inflammatory. Mallinckrodt said they plan to expand the Acthar market internationally.
Questcor's net sales grew 57%, to $799 million in 2013.